The 36-month beta value for EBS is also noteworthy at 1.65. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for EBS is 52.06M, and at present, short sellers hold a 13.35% of that float. The average trading volume of EBS on November 12, 2024 was 2.41M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
EBS) stock’s latest price update
Emergent Biosolutions Inc (NYSE: EBS) has experienced a decline in its stock price by -7.76 compared to its previous closing price of 11.97. However, the company has seen a gain of 23.22% in its stock price over the last five trading days. seekingalpha.com reported 2024-11-08 that Emergent BioSolutions’ Q3 earnings report led to a 20% surge in its share price, now valued at ~$11 per share. The company’s market cap is approximately $595 million, reflecting investor confidence post-earnings announcement. Emergent focuses on innovative preparedness and response solutions for various public health threats.
EBS’s Market Performance
Emergent Biosolutions Inc (EBS) has seen a 23.22% rise in stock performance for the week, with a 22.68% gain in the past month and a 45.85% surge in the past quarter. The volatility ratio for the week is 9.30%, and the volatility levels for the past 30 days are at 7.78% for EBS. The simple moving average for the past 20 days is 14.24% for EBS’s stock, with a 77.60% simple moving average for the past 200 days.
Analysts’ Opinion of EBS
Many brokerage firms have already submitted their reports for EBS stocks, with Rodman & Renshaw repeating the rating for EBS by listing it as a “Buy.” The predicted price for EBS in the upcoming period, according to Rodman & Renshaw is $16 based on the research report published on August 22, 2024 of the current year 2024.
The Benchmark Company, on the other hand, stated in their research note that they expect to see EBS reach a price target of $5. The rating they have provided for EBS stocks is “Buy” according to the report published on March 07th, 2024.
EBS Trading at 28.73% from the 50-Day Moving Average
After a stumble in the market that brought EBS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.88% of loss for the given period.
Volatility was left at 7.78%, however, over the last 30 days, the volatility rate increased by 9.30%, as shares surge +17.85% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +46.55% upper at present.
During the last 5 trading sessions, EBS rose by +20.87%, which changed the moving average for the period of 200-days by +491.80% in comparison to the 20-day moving average, which settled at $9.65. In addition, Emergent Biosolutions Inc saw 360.04% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EBS starting from White Marvin L, who proposed sale 14,287 shares at the price of $11.77 back on Nov 11 ’24. After this action, White Marvin L now owns shares of Emergent Biosolutions Inc, valued at $168,158 using the latest closing price.
Zoon Kathryn C, the Director of Emergent Biosolutions Inc, sale 10,000 shares at $6.11 during a trade that took place back on Jun 04 ’24, which means that Zoon Kathryn C is holding 54,482 shares at $61,100 based on the most recent closing price.
Stock Fundamentals for EBS
Current profitability levels for the company are sitting at:
- -0.09 for the present operating margin
- 0.39 for the gross margin
The net margin for Emergent Biosolutions Inc stands at -0.19. The total capital return value is set at -0.08. Equity return is now at value -34.64, with -12.39 for asset returns.
Based on Emergent Biosolutions Inc (EBS), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at 213.38. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -1.56.
Currently, EBITDA for the company is -42.9 million with net debt to EBITDA at 18.64. When we switch over and look at the enterprise to sales, we see a ratio of 0.4. The receivables turnover for the company is 9.08for trailing twelve months and the total asset turnover is 0.75. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.88.
Conclusion
In summary, Emergent Biosolutions Inc (EBS) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
